F*** Cancer, page-3

I think its most likely the CE mark will be approved in the 1st Qtr, 2018
Daniel Kelly confirmed in the recent conference call that he was very confident
that the CE mark will be approved
He also stated he will advise the market once 20 patients have been implanted,
and stated this will occur before the end of 2017
So once this happens, the required safety assessment will be sent to BSI
Then I think the CE mark will be approved soon after

Also noted that Daniel Kelly has 12,000,000 loan shares expiring 28-11-2017
Roger Aston also has 1,000,000 expiring on the same day with same conditions

​

ASX / Media Release
24th November 2014
ONCOSIL MEDICAL’S NEW CHIEF EXECUTIVE OFFICER TO RECEIVE INCENTIVE PACKAGE OF 12 MILLION EMPLOYEE LOAN SHARES
SYDNEY, Monday 24th November 2014: OncoSil Medical Limited (ASX: OSL) (OncoSil, the Company) advises that, further to the Company announcement of Tuesday 11th November, the Company’s new Chief Executive Officer, Mr Daniel Kenny, will receive 12 million Employee Loan Shares as part of his incentive package. Vesting of these shares will be subject to achievement of Key Performance Indicators over a three year period.
At the same time, 12 million Employee Loan Shares issued to Dr Neil Frazer will be cancelled. The issue of Employee Loan Shares to the new CEO will have no dilutive effect on shareholders.
Vesting of the Employee Loan Shares are dependent on achievement of Key Performance Indicators in four tranches:
Tranche 1 – Total Shareholder Returns of 175%.
Tranche 2 – Total Shareholder Returns of 250%.
Tranche 3 – US FDA approval for the OncoSilTM device.
Tranche 4 – attainment of three years of service.
The Company wishes to thank shareholders for their continuing support.

​